Sanofi reports shortages of two medicines used to treat Pompe disease, the company has informed clinicians and patient groups in the United States and Europe. The affected products are Myozyme, an established enzyme-replacement therapy, and Nexviazyme, a newer option. The advisories say supplies are diminishing after a bottleneck in the final manufacturing phase at the company’s Waterford, Ireland, facility, which was the subject of a recent regulatory notification from the U.S. Food and Drug Administration (FDA).
Batch release at the Waterford site refers to the final quality assurance and regulatory certification that clears manufactured lots for distribution. Sanofi communications attribute the constrained supply to a slowdown in that release step together with identified quality-control matters at the plant. The batch release process is intended to confirm that each lot meets established safety, potency and purity standards before it is shipped to hospitals, infusion centers and pharmacies.
Sanofi has alerted healthcare professionals and patient advocacy organizations to the potential for intermittent availability and urged clinicians to monitor local inventories. Pompe disease is a rare, progressive metabolic disorder that is managed with regular enzyme infusions; consistent access to therapy is important to preserve respiratory and motor function. Hospital pharmacies, specialty pharmacies and treating physicians are being asked to coordinate care and prioritize treatments according to clinical need while additional information is provided.
The FDA and the European Medicines Agency (EMA) oversee manufacturing oversight and batch release procedures in their respective jurisdictions and maintain mechanisms to track drug shortages and mitigation plans. Restoring routine supply will depend on resolution of the cited quality-control findings and formal release of cleared batches by the relevant regulators. Patients, clinicians and advocacy groups are awaiting further updates from Sanofi and national health authorities about timelines, contingency arrangements and any clinical guidance regarding treatment continuity.
